$2.05
-0.01 (-0.49%)
Open$2.16
Previous Close$2.06
Day High$2.25
Day Low$1.99
52W High$27.63
52W Low$19.00
Volume—
Avg Volume245.9K
Market Cap111.15M
P/E Ratio29.48
EPS$0.73
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+1,155.1% upside
Current
$2.05
$2.05
Target
$25.73
$25.73
$15.89
$25.73 avg
$34.39
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 18.10M | 17.71M | 19.64M |
| Net Income | 3.87M | 3.06M | 4.04M |
| Profit Margin | 21.4% | 17.3% | 20.6% |
| EBITDA | 5.83M | 6.29M | 6.55M |
| Free Cash Flow | 3.85M | 4.93M | 3.44M |
| Rev Growth | +0.2% | -1.6% | +10.4% |
| Debt/Equity | 0.48 | 0.65 | 0.65 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |